Kolon Life Sciences said on Jan. 14 that it has signed an agreement with Mundipharma of the United States to export 100 billion won (US$89.75 million) worth of Invossa, the world's first cell and gene therapy for osteoarthritis, to nine countries.Under the terms of the agreement, Mundipharma wil
The Kolon Group is striving to boost its competitiveness in the pharmaceutical and biotechnology business through cooperation with Korean and foreign partners. The group plans to become a mid-sized pharmaceutical company by signing co-promotion agreements with global pharmaceutical companies at home
Invossa, Korea's first gene therapy drug for knee osteoarthritis developed by the Kolon Group, made a foray into China, the largest market in Asia. Kolon signed a contract to supply 230 billion won (US$207 million) worth of Invossa to Henan Province in China for five years. The deal represents o
Invossa, South Korea’s first gene therapy for knee osteoarthritis developed by the Kolon Group, has crossed the final threshold for the phase 3 clinical trial in the US.Kolon TissueGene, an affiliate of the Kolon Group, announced on July 6 that the company has got approval of its use of the clinical
Lee Beom-seok, president of Kolon TissueGene Inc., is confident that the US Food and Drug Administration will give the green light to phase III clinical trials on Invossa, the world’s first knee osteoarthritis genetic therapy.“We have already secured 60 sites for the clinical trials and will add ano
Kolon Group was given the green light for exporting Invossa, the world's first cell gene-based osteoarthritis drug, to the Middle East.Lee Woong-yeol, chairman of the Kolon Group, met with Sheikh Saud Bin Saqr Al Qasimi, current emir of Ras Al Khaimah, who was visiting Korea in Kolon One & Only